Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1911 B-DASH: daratumumab versus daratumumab + bortezomib maintenance after D-MPB for untreated transplant-ineligible or transplant-refusing multiple myeloma
jRCTs031200320Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab, bortezomib, melphalan and prednisolone in multiple myeloma (MM) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival after second registration. Started Feb 2021; status: active, not recruiting.
02
Drugs
daratumumabbortezomibmelphalanprednisolone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031200320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200320.